Citi Has Buy on J&J

Citi Investment Research is out with a research report on Johnson & Johnson Inc

and it has a Buy rating and a $72 price target on shares. In a note to clients, Citi Investment Research writes, "The ATLAS data backed the 9/30 preliminary release that the primary endpoint was met, but only showed a small net clinical benefit due to higher bleeding rates. While this data should still position Xarelto as the only oral anticoagulant (OAC) to gain ACS approval, it will likely create more uncertainty around the entire class for SFAF/ACS co-morbidity usage due to a reverse dose response." Shares of JNJ gained $1.13 on Friday to close at $65.25.